Ipca Laboratories has announced the incorporation of its wholly owned subsidiary, Ipca Pharmaceuticals GmbH, in the Federal Republic of Germany with an initial paid-up capital of Euro 25,000.

The new entity has been established to hold product registrations, participate in institutional and other business opportunities, and manage the distribution of generic formulations in Germany.  

Ipca Laboratories manufactures more than 350 formulations and 80 active pharmaceutical ingredients (APIs) across diverse therapeutic areas. The company is also among India’s leading exporters of APIs, supplying products to over 70 countries worldwide.

Founded in 1949, Ipca’s global manufacturing footprint now spans 15 locations, including API facilities in North Carolina, USA, and Sunderland, United Kingdom. The establishment of its German subsidiary marks another step in Ipca’s strategic expansion into key international markets.